Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment

Παρόμοια τεκμήρια

• Does treat to target or achieving remission improve radiographic outcome in psa?
  ανά: Coates, L, κ.ά.
  Έκδοση: (2016)
• Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
  ανά: Coates, LC, κ.ά.
  Έκδοση: (2022)
• Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
  ανά: McGagh, D, κ.ά.
  Έκδοση: (2020)
• Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
  ανά: Coates, LC, κ.ά.
  Έκδοση: (2021)
• Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
  ανά: Coates, LC, κ.ά.
  Έκδοση: (2021)